IMRX - What's Going On With Cancer-Focused Immuneering Stock On Thursday? | Benzinga
Thursday, Immuneering Corporation (NASDAQ:IMRX) revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-1-104 in advanced RAS-mutant solid tumors.
As of February 20, 2024 (N=19), patient plasma data showed IMM-1-104 at 320mg inhibiting phosphorylated extracellular signal-regulated kinase at a level of 90% or greater for 2.7 hours before returning to near-zero levels in advance of 24 hours.
IMM-1-104 at a 240mg dose achieved 90% or greater levels of pERK inhibition for 1.9 hours before returning to near-zero levels in advance of 24 hours.
Immuneering evaluated 240mg and 320mg QD as prospective doses for the Phase ...